|
|
|
Insider
Information: |
Lampert Mark N |
Relationship: |
10% Owner |
City: |
San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
44 |
|
Direct
Shares |
110,838,010 |
|
Indirect Shares
|
88,557,834 |
|
|
Direct
Value |
$1,189,515,197 |
|
|
Indirect Value
|
$1,625,984,852 |
|
|
Total
Shares |
199,395,844 |
|
|
Total
Value |
$2,815,500,049 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
51
|
13
|
Stock
price went up :
|
41
|
4
|
Stock
price went down : |
10
|
9
|
|
|
|
Gain/Loss Ratio : |
4.1
|
4.1
|
Percentage
Gain/Loss : |
101.4%
|
-82.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Arena Pharmaceuticals Inc |
ARNA |
Director, 10% Owner |
2003-10-17 |
0 |
2003-10-17 |
4,520,212 |
Premium* |
|
Repligen Corp |
RGEN |
10% Owner |
2009-05-15 |
3,216,850 |
|
0 |
Premium* |
|
Dynavax Technologies Corp |
DVAX |
Indirect Beneficial Ow... |
2009-06-19 |
6,193,051 |
2009-06-19 |
18,579,153 |
Premium* |
|
Adolor Corp |
ADLR |
10% Owner |
2009-09-22 |
4,123,551 |
2009-09-22 |
12,370,653 |
Premium* |
|
Gyre Therapeutics |
GYRE |
10% Owner |
|
0 |
2012-11-08 |
1,052,258 |
Premium* |
|
Arqule Inc |
ARQL |
10% Owner |
2018-05-30 |
771,305 |
2010-04-05 |
12,624,219 |
Premium* |
|
Astex Pharmaceuticals Inc |
ASTX |
10% Owner |
2010-04-20 |
5,583,399 |
2010-04-20 |
16,750,197 |
Premium* |
|
Capstone Therapeutics Corp |
CAPS |
See Explanation of Res... |
2011-06-27 |
0 |
2017-07-14 |
890,487 |
Premium* |
|
Ligand Pharmaceuticals Inc |
LGND |
See Explanation of Res... |
|
0 |
2014-03-25 |
130,175 |
Premium* |
|
Icagen Inc |
ICGN |
10% Owner |
2011-09-07 |
0 |
2011-09-07 |
625,400 |
Premium* |
|
Palatin Technologies Inc |
PTN |
10% Owner |
|
0 |
2014-02-27 |
2,494,521 |
Premium* |
|
Neurocrine Biosciences Inc |
NBIX |
10% Owner |
2011-10-10 |
0 |
2011-10-12 |
3,527,700 |
Premium* |
|
Kent International Inc |
KNTH |
See Explanation of Res... |
2011-12-23 |
0 |
2011-12-23 |
0 |
Premium* |
|
Chemocentryx, Inc. |
CCXI |
10% Owner |
|
0 |
2012-11-06 |
3,750,277 |
Premium* |
|
Rigel Pharmaceuticals Inc |
RIGL |
10% Owner |
|
0 |
2013-06-07 |
7,761,738 |
Premium* |
|
Cascadian Therapeutics, Inc |
CASC |
10% Owner |
2013-06-05 |
0 |
2015-02-05 |
1,898,293 |
Premium* |
|
Tobira Therapeutics Inc |
TBRA |
See Explanation of Res... |
|
0 |
2014-03-21 |
1,121,221 |
Premium* |
|
Cti Biopharma Corporation |
CTIC |
See Explanation of Res... |
2023-06-26 |
0 |
2023-06-26 |
0 |
Premium* |
|
Infinity Pharmaceuticals Inc |
INFI |
10% Owner |
2021-02-11 |
534,847 |
2016-12-01 |
0 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2023-01-06 |
1,693,924 |
2023-01-06 |
361,774 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
10% Owner |
2017-06-20 |
201,811 |
2017-05-09 |
0 |
Premium* |
|
Glycomimetics Inc |
GLYC |
10% Owner |
2020-11-04 |
630,453 |
|
0 |
Premium* |
|
Xenon Pharmaceuticals Inc. |
XENE |
10% Owner |
2018-03-27 |
59,464 |
2017-06-06 |
0 |
Premium* |
|
Concert Pharmaceuticals, Inc. |
CNCE |
10% Owner |
2019-06-10 |
169,589 |
2017-10-19 |
0 |
Premium* |
|
Syndax Pharmaceuticals Inc |
SNDX |
10% Owner |
2018-06-18 |
85,038 |
2018-06-18 |
0 |
Premium* |
|
Immune Design Corp. |
IMDZ |
10% Owner |
2018-12-04 |
370,391 |
2018-12-04 |
0 |
Premium* |
|
Pieris Pharmaceuticals, Inc. |
PIRS |
10% Owner |
2023-05-11 |
20,333,557 |
2019-01-30 |
0 |
Premium* |
|
Calithera Biosciences, Inc. |
CALA |
10% Owner |
2020-05-21 |
480,432 |
|
0 |
Premium* |
|
Five Prime Therapeutics Inc |
FPRX |
10% Owner |
2021-03-04 |
6,262,085 |
|
0 |
Premium* |
|
Cytokinetics Inc |
CYTK |
See Explanation of Res... |
2020-12-09 |
463,244 |
2019-12-10 |
0 |
Premium* |
|
Merus Nv |
MRUS |
10% Owner |
2021-10-08 |
232,747 |
|
0 |
Premium* |
|
Ideaya Biosciences, Inc. |
IDYA |
See Explanation of Res... |
2021-02-02 |
233,150 |
2020-06-19 |
0 |
Premium* |
|
Kymera Therapeutics, Inc. |
KYMR |
See Remarks and Footno... |
2023-11-03 |
294,632 |
2020-08-21 |
0 |
Premium* |
|
Eledon Pharmaceuticals Ord Shs |
ELDN |
10% Owner |
2024-05-09 |
220,460 |
|
0 |
Premium* |
|
Olema Pharmaceuticals, Inc. |
OLMA |
Director, 10% Owner |
2023-09-12 |
524,151 |
2023-09-14 |
99,556 |
Premium* |
|
Cytomx Therapeutics, Inc. |
CTMX |
10% Owner |
2020-12-18 |
5,468,599 |
|
0 |
Premium* |
|
Rain Therapeutics Inc. |
RAIN |
See Remarks; Former 10... |
2024-01-25 |
0 |
2021-04-23 |
0 |
Premium* |
|
Repare Therapeutics Inc. |
RPTX |
10% Owner |
2023-11-16 |
548,938 |
|
0 |
Premium* |
|
Verastem, Inc. |
VSTM |
10% Owner |
2022-01-25 |
19,630,934 |
|
0 |
Premium* |
|
ESSA Pharma Inc |
EPIX |
10% Owner |
2022-07-11 |
8,561,841 |
|
0 |
Premium* |
|
Third Harmonic Bio, Inc. |
THRD |
10% Owner |
2022-12-20 |
241,309 |
2022-12-20 |
0 |
Premium* |
|
Structure Therapeutics Inc. |
GPCR |
10% Owner |
2023-05-10 |
5,173,941 |
|
0 |
Premium* |
|
Engene Holdings Inc. |
ENGN |
10% Owner |
2023-10-31 |
2,221,445 |
|
0 |
Premium* |
|
Allakos Inc. |
ALLK |
10% Owner |
2024-01-16 |
16,312,872 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
356 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 15
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ADLR |
Adolor Corp |
Indirect Beneficial Owner |
|
2009-06-19 |
4/A |
S |
$2.00 |
$42,970 |
D/D |
(21,500) |
6,193,051 |
0 |
- |
|
ADLR |
Adolor Corp |
Direct Beneficial Owner |
|
2009-07-13 |
4 |
S |
$1.67 |
$1,172,917 |
D/D |
(700,500) |
5,492,551 |
0 |
- |
|
ADLR |
Adolor Corp |
Direct Beneficial Owner |
|
2009-07-14 |
4 |
S |
$1.67 |
$41,760 |
D/D |
(25,000) |
5,467,551 |
0 |
- |
|
ADLR |
Adolor Corp |
Direct Beneficial Owner |
|
2009-09-14 |
4 |
S |
$1.79 |
$169,851 |
D/D |
(95,000) |
5,372,551 |
0 |
- |
|
ADLR |
Adolor Corp |
Direct Beneficial Owner |
|
2009-09-15 |
4 |
S |
$1.72 |
$610,600 |
D/D |
(355,000) |
5,017,551 |
0 |
- |
|
ADLR |
Adolor Corp |
Direct Beneficial Owner |
|
2009-09-16 |
4 |
S |
$1.71 |
$235,566 |
D/D |
(138,000) |
4,879,551 |
0 |
- |
|
ADLR |
Adolor Corp |
Direct Beneficial Owner |
|
2009-09-17 |
4 |
S |
$1.70 |
$183,600 |
D/D |
(108,000) |
4,771,551 |
0 |
- |
|
ADLR |
Adolor Corp |
Direct Beneficial Owner |
|
2009-09-18 |
4 |
S |
$1.66 |
$399,602 |
D/D |
(241,000) |
4,530,551 |
0 |
- |
|
ADLR |
Adolor Corp |
Direct Beneficial Owner |
|
2009-09-21 |
4 |
S |
$1.67 |
$88,537 |
D/D |
(53,000) |
4,477,551 |
0 |
- |
|
ADLR |
Adolor Corp |
Direct Beneficial Owner |
|
2009-09-22 |
4 |
S |
$1.69 |
$599,706 |
D/D |
(354,000) |
4,123,551 |
0 |
- |
|
ALLK |
Allakos Inc. |
10% Owner |
|
2024-01-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,312,872 |
|
% |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-05-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,702,810 |
|
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-05-09 |
4 |
B |
$2.29 |
$91,516 |
D/D |
40,000 |
171,536 |
2.45 |
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-05-10 |
4 |
B |
$2.35 |
$145,433 |
D/D |
62,000 |
177,753 |
2.45 |
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-05-11 |
4 |
B |
$2.34 |
$16,480 |
D/D |
7,034 |
178,428 |
2.37 |
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-05-17 |
4 |
B |
$2.30 |
$85,907 |
D/D |
37,372 |
183,938 |
2.45 |
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-05-18 |
4 |
B |
$2.30 |
$68,732 |
D/D |
29,886 |
186,847 |
2.45 |
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-05-19 |
4 |
B |
$2.30 |
$26,680 |
D/D |
11,600 |
187,971 |
2.37 |
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-05-30 |
4 |
B |
$2.30 |
$43,389 |
D/D |
18,900 |
189,776 |
2.37 |
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-05-31 |
4 |
B |
$2.25 |
$63,141 |
D/D |
28,100 |
192,503 |
2.45 |
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-06-05 |
4 |
B |
$2.29 |
$81,889 |
D/D |
35,750 |
196,423 |
2.45 |
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-06-07 |
4 |
B |
$2.28 |
$84,180 |
D/D |
36,900 |
200,096 |
2.45 |
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2017-06-20 |
4 |
B |
$2.25 |
$40,064 |
D/D |
17,806 |
201,811 |
2.37 |
- |
|
ARNA |
Arena Pharmaceuticals Inc |
Director |
|
2003-10-17 |
4 |
S |
$7.69 |
$22,385,590 |
I/I |
(2,911,000) |
4,520,212 |
|
- |
|
ARQL |
Arqule Inc |
Direct Beneficial Owner |
|
2009-09-17 |
4 |
S |
$5.25 |
$19,320,000 |
D/D |
(3,680,000) |
8,564,073 |
0 |
- |
|
356 Records found
|
|
Page 1 of 15 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|